137 related articles for article (PubMed ID: 22560713)
1. Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Fairchild A; Weber DC; Bar-Deroma R; Gulyban A; Fenton PA; Stupp R; Baumert BG
Radiother Oncol; 2012 Jun; 103(3):287-92. PubMed ID: 22560713
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Abrunhosa-Branquinho AN; Bar-Deroma R; Collette S; Clementel E; Liu Y; Hurkmans CW; Feuvret L; Van Beek K; van den Bent M; Baumert BG; Weber DC
Radiother Oncol; 2018 May; 127(2):292-298. PubMed ID: 29606522
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Ataman F; Poortmans P; Stupp R; Fisher B; Mirimanoff RO
Eur J Cancer; 2004 Jul; 40(11):1724-30. PubMed ID: 15251162
[TBL] [Abstract][Full Text] [Related]
4. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Musat E; Roelofs E; Bar-Deroma R; Fenton P; Gulyban A; Collette L; Stupp R; Weber DC; Bernard Davis J; Aird E; Baumert BG
Radiother Oncol; 2010 May; 95(2):218-24. PubMed ID: 20378192
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
6. Promises and controversies in the management of low-grade glioma.
Stupp R; Baumert BG
Ann Oncol; 2003 Dec; 14(12):1695-6. PubMed ID: 14630671
[No Abstract] [Full Text] [Related]
7. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Broniscer A; Chintagumpala M; Fouladi M; Krasin MJ; Kocak M; Bowers DC; Iacono LC; Merchant TE; Stewart CF; Houghton PJ; Kun LE; Ledet D; Gajjar A
J Neurooncol; 2006 Feb; 76(3):313-9. PubMed ID: 16200343
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the medical treatment of glioma-temozolomide].
Nishikawa R
No To Shinkei; 2006 Dec; 58(12):1035-41. PubMed ID: 17193953
[No Abstract] [Full Text] [Related]
10. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
11. Combined radiotherapy and temozolomide in patients with recurrent high grade glioma.
Schönekaes K; Mücke R; Panke J; Rama B; Wagner W
Tumori; 2002; 88(1):28-31. PubMed ID: 12004846
[TBL] [Abstract][Full Text] [Related]
12. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Charnley N; West CM; Barnett CM; Brock C; Bydder GM; Glaser M; Newlands ES; Swindell R; Matthews J; Price P
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):331-8. PubMed ID: 16839701
[TBL] [Abstract][Full Text] [Related]
13. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Cao Y; Tsien CI; Shen Z; Tatro DS; Ten Haken R; Kessler ML; Chenevert TL; Lawrence TS
J Clin Oncol; 2005 Jun; 23(18):4127-36. PubMed ID: 15961760
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Narayana A; Golfinos JG; Fischer I; Raza S; Kelly P; Parker E; Knopp EA; Medabalmi P; Zagzag D; Eagan P; Gruber ML
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):383-9. PubMed ID: 18793954
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
[TBL] [Abstract][Full Text] [Related]
16. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.
Baumert BG; Brada M; Bernier J; Kortmann RD; Dehing-Oberije C; Collette L; Davis JB
Radiother Oncol; 2008 Aug; 88(2):163-72. PubMed ID: 18455252
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Rapp M; Sadat H; Slotty PJ; Steiger HJ; Budach W; Sabel M
J Neurol Surg A Cent Eur Neurosurg; 2015 Jul; 76(4):298-302. PubMed ID: 25915500
[TBL] [Abstract][Full Text] [Related]
19. Going past the data for temozolomide.
Villano JL; Letarte N; Bressler LR
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1113-5. PubMed ID: 22147076
[TBL] [Abstract][Full Text] [Related]
20. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
